Compare · MDLN vs NVNO
MDLN vs NVNO
Side-by-side comparison of Medline Inc. (MDLN) and enVVeno Medical Corporation (NVNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVNO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 8731.3x NVNO ($5.5M).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 1 for NVNO).
- MDLN has more recent analyst coverage (25 ratings vs 0 for NVNO).
- Company
- Medline Inc.
- enVVeno Medical Corporation
- Price
- -
- -
- Market cap
- $48.08B
- $5.5M
- 1M return
- -
- -14.68%
- 1Y return
- -
- -70.57%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2018
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 0
enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest NVNO
- enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
- enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
- Director Duhay Francis sold $123 worth of shares (11 units at $11.21) as part of a pre-agreed trading plan, decreasing direct ownership by 0.47% to 2,351 units (SEC Form 4)
- enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
- enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
- JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
- SEC Form S-3 filed by enVVeno Medical Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation
- Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
- enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve